Elisa Agostinetto: The sub-analysis of the EMERALD trial

Elisa Agostinetto shared on X:

“The sub-analysis of the EMERALD trial by Prior Duration of CDK4/6i plus ET presented at SABCS is now published. Duration of prior ET+CDK4/6i ≥12 months is associated with an increased PFS with elacestrant.”

Source: Elisa Agostinetto/X

Authors: Aditya Bardia, Javier Cortes, Francois-Clement Bidard, Patrick Neven, Jose Garcia-Saenz, Philippe Aftimos, Joyce O’Shaughnessy, Janice Lu, Giulia Tonini, Simona Scartoni, Alessandro Paoli, Monica Binaschi, Tomer Wasserman, Virginia Kaklamani

Elacestrant in ER+, HER2– MBC with ESR1-mutated tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy Plus CDK4/6 Inhibitor and in Clinical Subgroups 

Dr. Elisa Agostinetto, is a medical oncologist, specializing in breast cancer research. Elisa Agostinetto is a Medical Research Fellow at the University Hospital of Brussels since November 2021. Additionally, she has serves as a Clinical Research Fellow at Jules Bordet Institute. Her work focuses on clinical research in oncology, likely involving various aspects of cancer treatment and patient care.

Actively engaged in professional societies like ESMO, ASCO, and BSMO, she also contributes as a young investigator in the EORTC Breast Cancer Working Group and as a Committee member of the Young Cancer Professionals within the European Cancer Organization.